Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels

ObjectiveTo investigate the utility of random anti-Müllerian hormone (AMH) in assessing ovarian response among women with diminished ovarian reserve (DOR) diagnosed by elevated early follicular-phase FSH levels.DesignRetrospective study.SettingAcademic and academically affiliated assisted reproductive technology (ART) programs.Patient(s)Seventy-three women undergoing ART with elevated early follicular FSH levels.Intervention(s)None.Main Outcome Measure(s)Number of oocytes retrieved during ART cycle, number of day 3 embryos, and cycle cancellation and clinical pregnancy rates.Result(s)Random AMH levels were strongly correlated with the number of oocytes retrieved during an ART cycle among women with elevated FSH (r = 0.55). Women with elevated FSH who had a random serum AMH level of 0.6 ng/mL or higher had twice the number of oocytes retrieved (11 ± 1.3 vs. 5.6 ± 0.6), a greater number of day 3 embryos (5.7 ± 0.9 vs. 3 ± 0.5), and approximately a third of the cycle cancellation rate (14% vs. 41%) compared with women with a random serum AMH below 0.6 ng/mL. The clinical pregnancy rate was also higher among women with a random serum AMH ≥0.6 ng/mL (28% vs. 14%), however, the difference was not statistically significant.Conclusion(s)A random serum AMH level is useful in setting expectations for ART prognosis in women with elevated early follicular-phase serum FSH levels.